Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.16EUR
15 Feb 2019
Change (% chg)

€-0.03 (-0.94%)
Prev Close
€3.19
Open
€3.17
Day's High
€3.19
Day's Low
€3.15
Volume
42,237
Avg. Vol
80,246
52-wk High
€4.19
52-wk Low
€3.01

Latest Key Developments (Source: Significant Developments)

Valneva Sees 2019 Total Revenues In Range Of EUR 125-135 Million
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - VALNEVA SE ::REG-VALNEVA CONFIRMS FY 2018 GUIDANCE AND PROVIDES INITIAL PRODUCT SALES REVENUE GUIDANCE FOR 2019.CONFIRMED THAT IT EXPECTS 2018 PRODUCT SALES REVENUES TO REACH BETWEEN EUR 100 MILLION AND EUR 105 MILLION.2018 PRODUCT SALES GROWTH IS PRIMARILY BEING DRIVEN BY INCREASING IXIARO(® )SALES.IN 2019, COMPANY PROJECTS THAT PRODUCT SALES REVENUES WILL GROW TO BETWEEN EUR 115 MILLION TO EUR 125 MILLION WHILE OTHER REVENUES SHOULD REMAIN AT SIMILAR LEVELS TO 2018.IN 2019 TOTAL REVENUES WILL BE IN RANGE OF EUR 125 MILLION TO EUR 135 MILLION.  Full Article

Valneva Intends To Delist From Vienna Stock Exchange
Monday, 7 Jan 2019 

Jan 7 (Reuters) - VALNEVA SE ::REG-VALNEVA ANNOUNCES ITS INTENTION TO DELIST FROM THE VIENNA STOCK EXCHANGE.TRADING WILL BE CENTRALIZED ON EURONEXT PARIS.  Full Article

Valneva Reports Phase 1 Results For Chikungunya Vaccine
Monday, 7 Jan 2019 

Jan 7 (Reuters) - VALNEVA SE ::VALNEVA REPORTS POSITIVE PHASE 1 INTERIM RESULTS FOR ITS CHIKUNGUNYA VACCINE CANDIDATE.100% SEROCONVERSION RATE ACHIEVED AT DAY 28 AFTER A SINGLE-SHOT VACCINATION IN A POOLED ANALYSIS OF ALL DOSE GROUPS.NO SERIOUS ADVERSE EVENTS OR ADVERSE EVENTS OF SPECIAL INTEREST WERE REPORTED UP TO DAY 28.  Full Article

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
Monday, 17 Dec 2018 

Dec 17 (Reuters) - VALNEVA SE ::VALNEVA INITIATES PHASE 2 CLINICAL DEVELOPMENT FOR ITS LYME DISEASE VACCINE CANDIDATE.PHASE 2 DURATION IS EXPECTED TO BE APPROXIMATELY TWO YEARS WITH INTERIM DATA (PRIMARY ENDPOINT) EXPECTED MID-2020.PHASE 2 DEVELOPMENT WILL INCLUDE THE EVALUATION OF THE HIGHEST DOSE OF VLA15 TESTED IN PHASE 1 IN ADDITION TO TWO HIGHER DOSES.PHASE 2 OBJECTIVE FOR VLA15 IS TO DETERMINE THE OPTIMAL DOSAGE LEVEL AND SCHEDULE FOR USE IN PHASE 3 PIVOTAL FIELD EFFICACY STUDIES.  Full Article

Valneva Receives Positive Feedback From EMA On Its Further Development For VLA15
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - VALNEVA SE ::VALNEVA RECEIVES POSITIVE FEEDBACK FROM EMA ON ITS FURTHER DEVELOPMENT FOR LYME DISEASE VACCINE VLA15.THE COMPANY CONFIRMS IT EXPECTS TO ENTER PHASE 2 CLINICAL DEVELOPMENT AT THE END OF 2018..  Full Article

Valneva Receives Positive Feedback From EMA On Development Of Vaccine VLA15
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - VALNEVA SE ::RECEIVES POSITIVE FEEDBACK FROM EMA ON ITS FURTHER DEVELOPMENT FOR LYME DISEASE VACCINE VLA15.  Full Article

Valneva Announces FDA Approval Of Accelerated IXIARO Vaccination Schedule
Friday, 5 Oct 2018 

Oct 5 (Reuters) - VALNEVA SE ::VALNEVA ANNOUNCES FDA APPROVAL OF ACCELERATED IXIARO VACCINATION SCHEDULE.FDA APPROVED ALTERNATE IXIARO IMMUNIZATION SCHEDULE OF 2 DOSES ADMINISTERED 7 DAYS APART FOR ADULT TRAVELERS AGED 18-65 YRS OLD.  Full Article

Oddo BHF Says Valneva Placement Priced At 3.75 Euros
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - ODDO BHF::VALNEVA PLACEMENT : SIZE INCREASED FROM 40M€ TO 50M€ THANKS TO VERY STRONG TRACTION, ESPECIALLY FROM USA .VALNEVA PLACEMENT : PRICING SET AT 3.75€ REPRESENTING 2.6% DISCOUNT VERSUS 3 DAYS VWAP.  Full Article

Valneva Reports EBITDA of 5.8 Million Euros In H1
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - VALNEVA SE ::REG-VALNEVA DELIVERS STRONG IXIARO® SALES GROWTH AND REPORTS FURTHER PROGRESS ON KEY RESEARCH AND DEVELOPMENT PROGRAMS IN H1.PRODUCT SALES OF EUR 53.5 MILLION IN H1 2018, REPRESENTING 11.4% YEAR ON YEAR.STRONG IXIARO(® )SALES REVENUE GROWTH OF OVER 19% DRIVEN BY US PRIVATE MARKET.TOTAL REVENUES WERE EUR 59.0 MILLION IN H1 2018 (VERSUS. EUR 53.9 MILLION IN H1 2017).EBITDA OF EUR 5.8 MILLION IN H1 2018, IN LINE WITH COMPANY 2018 GUIDANCE OF EUR 5.0 MILLION TO EUR 10.0 MILLION.PHASE 2 PREPARATION ACTIVITIES ONGOING FOR COMPANY'S LYME VACCINE CANDIDATE EXPECTED TO ENTER PHASE 2 AT END OF 2018.RECRUITMENT COMPLETED FOR PHASE 1 STUDY OF COMPANY'S CHIKUNGUNYA VACCINE CANDIDATE. RESULTS EXPECTED EARLY 2019.RECRUITMENT COMPLETED FOR PHASE 1 STUDY OF COMPANY'S ZIKA VACCINE CANDIDATE. RESULTS EXPECTED AT END OF 2018 OR EARLY 2019.H1 NET LOSS EUR 0.2 MILLION VERSUS LOSS OF EUR 4.4 MILLION YEAR AGO.  Full Article

Valneva Announces Update For Lyme Disease Vaccine Candidate VLA15
Monday, 2 Jul 2018 

July 2 (Reuters) - VALNEVA SE ::ANNOUNCED TODAY FURTHER UPDATE FOR ITS LYME DISEASE VACCINE CANDIDATE, VLA15.SUCCESSFULLY CONCLUDED END OF PHASE 1 PROCESS FOR THIS CANDIDATE WITH FOOD AND DRUG ADMINISTRATION (FDA) AND HAS OBTAINED ALIGNMENT WITH REGARD TO ITS PHASE 2 STRATEGY.HAS OBTAINED ALIGNMENT WITH REGARD TO ITS PHASE 2 STRATEGY.NOW FINALIZING DETAILED PHASE 2 PROTOCOL AND, SUBJECT TO REQUISITE REGULATORY APPROVALS.EXPECTS TO ENTER PHASE 2 CLINICAL DEVELOPMENT BY END OF 2018.WILL PROVIDE A FULL UPDATE ON ITS LYME PROGRAM DURING PUBLICATION OF ITS H1 RESULTS ON AUGUST 2, 2018.  Full Article

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.